Clinical evidence on traditional HF therapies with treatments such as beta-blockade, mineralocorticoid receptor antagonists (MRA), and renin-angiotensin-aldosterone inhibition (RAASi) in ATTR-CM is limited. This evidence concerns the gene NR3C2 and hydrops fetalis.